|
|
|
| Application Value of HSF2,IL-23,and MDC in the Evaluation of Ulcerative Colitis |
| SONG Mei-nan |
| Puyang Oilfield General Hospital,Puyang Henan 457001 |
|
|
|
|
Abstract 【Objective】 To investigate the value of heat shock transcription factor 2 (HSF2),interleukin 23 (IL-23),and myeloid dendritic cells (MDC) in the evaluation of ulcerative colitis. 【Methods】 A total of 146 patients with UC admitted to our hospital from June 2019 to August 2021 (observation group) were selected,and another 73 healthy volunteers were selected as the control group. The serum levels of HSF2,IL-23,and MDC were compared between the observation group,the control group,and patients with UC of different conditions at admission. Pearson was used to analyze the correlation between the above indicators and the patient's condition,and the diagnostic value of the receiver operational characteristic curve (ROC curve) was used to analyze its diagnostic value for UC. 【Results】 The serum levels of HSF2,IL-23,and MDC in the observation group were significantly higher than those in the control group (P<0.05). The serum levels of HSF2,IL-23,and MDC in the active phase group were significantly higher than those in the remission phase group (P<0.05). The levels of serum HSF2,IL-23,and MDC in the three groups of patients were statistically significant (P<0.05). Pearson correlation analysis showed that the serum levels of HSF2,IL-23,and MDC were positively correlated with the onset period and severity of the disease (all P<0.05). The ROC curve analysis showed that the area under the curve (AUC) of serum HSF2,IL-23,and MDC levels for the diagnosis of UC was 0.795,0.832,and 0.856,respectively. The combined diagnosis AUC was 0.927,which was greater than a single indicator (P<0.05). 【Conclusion】 The serum levels of HSF2,IL-23,and MDC have certain evaluation value for the severity of UC patients,and can provide a reference for the clinical early diagnosis of UC.
|
|
Received: 13 July 2022
|
|
|
|
|
|
[1] 周慧文.健脾类方剂治疗溃疡性结肠炎的临床研究进展[J].中国中医药图书情报杂志,2022,46(2):71-76.
[2] LASA J S. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis:a systematic review and network meta-analysis[J].Lancet Gastroenterol Hepatol,2022,7(2):161-170.
[3] 杨夏,王秀丽,李伟.不同病情溃疡性结肠炎患者肠道菌群数目与其辅助性T细胞17、调节性T细胞免疫平衡的相关性[J].中国医学工程,2022,30(6):103-106.
[4] 阮水良,官俏兵.热休克转录因子2通过HMGB1-TLR4-NF-κB信号促进克罗恩病炎症反应的作用机制研究[J].中国临床药理学与治疗学,2019,24(4):369-375.
[5] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见(2012年)[J].胃肠病学,2012,17(12):763-781.
[6] DIGNASS A,RAMI E,MAGRO F,et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1:Definitions and diagnosis[J].J Crohns Colitis,2012,6(10):965-990.
[7] BERINSTEIN J A,SHEEHAN J L,DIAS M,et al.Tofacitinib for Biologic-experienced hospitalized patients with acute severe ulcerative colitis:a retrospective case-control study[J].Clin Gastroenterol Hepatol,2021,19(10):2112-2120.
[8] 张琳,魏凯艳,刘益娟.普拉梭菌对溃疡性结肠炎不典型增生患者Treg细胞水平及IL-23/IL-17轴的影响[J].中国病原生物学杂志,2022,17(2):224-228.
[9] BUNTE K,BEIKLER T.Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases[J].Int J Mol Sci,2019,20(14):3394.
[10] 蒋银芬,周燕.血清IL-23、TNF-α表达与溃疡性结肠炎患者中医辨证分型及病变程度的相关性[J].淮海医药,2022,40(1):27-30.
[11] 矫树华,蔡爽,温艳惠.血清IL-23、vaspin和fstl1水平在溃疡性结肠炎病情评估中的价值[J].山东医药,2015,55(13):44-45.
[12] 常旭.血清IL-23和IL-17水平变化在溃疡性结肠炎临床诊断中的应用价值[J].中国现代药物应用,2017,11(2):68-70.
[13] WEN Y,NIU J,ZHANG F,et al.Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis[J].Scand J Gastroenterol,2020,55(6):677-686.
[14] 陈怡,贾杰,郑娟红.重症溃疡性结肠炎患者外周血中髓样树突状细胞和IL-17A表达及预后研究[J].中华全科医学,2020,18(5):734-738. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1273-1275. |
|
|
|
|
2023, Vol. 40 
